Georgia Southern University

Digital Commons@Georgia Southern
Biostatistics Faculty Presentations

Biostatistics, Department of

11-2009

Analysis of Subgroup Data in Clinical Trials
Kao-Tai Tsai
Georgia Southern University

Karl E. Peace
Georgia Southern University, kepeace@georgiasouthern.edu

Follow this and additional works at: https://digitalcommons.georgiasouthern.edu/biostat-facpres
Part of the Biostatistics Commons, and the Public Health Commons
Recommended Citation
Tsai, Kao-Tai, Karl E. Peace. 2009. "Analysis of Subgroup Data in Clinical Trials." Biostatistics Faculty Presentations. Presentation 1.
https://digitalcommons.georgiasouthern.edu/biostat-facpres/1

This conference proceeding is brought to you for free and open access by the Biostatistics, Department of at Digital Commons@Georgia Southern. It
has been accepted for inclusion in Biostatistics Faculty Presentations by an authorized administrator of Digital Commons@Georgia Southern. For
more information, please contact digitalcommons@georgiasouthern.edu.

Subgroup Data Analyses of
Clinical Trials - Issues & Methods
Kao-Tai Tsai1 & Karl E. Peace2
1Presented at BASS XVI
Mulberry Inn Suites
Savannah, Georgia
November 10, 2009
1tsai0123@yahoo.com
2kepeace@georgiasouthern.edu

Analysis of Subgroups: Revisiting an old issue
A.1985: Protocol Ho:C800 mg = 0 vs. Ha:C800 mg > 0 the elderly;
- Subset the database from a large (n = 771) trial of
C1600 vs C800 vs C400 vs C0 ; all hs: found # elderly = 101;
{95%/90% CI on (C800 – C0) = (10% - 66%) / (14% - 62%}.
- Recommended N = 0 for the protocol

B.1986: Developed Protocol with 95% power
- Randomization within each of two strata
- Each Stratum: approximately 75% power
- Analysis plan: Within Strata (Unconditional); if both significant, claim
reproducibility had been demonstrated, and the two adequate
and well-controlled requirement was met. If not; analyze as
one protocol.

C. IND/NDA Rewrite which gave signal that NDAs should do due
diligence regarding inference to demographic subgroups.
D. 1994 DIA Workshop: Drug Development Strategies for
Subpopulations.
- Peace KE: What’s the Question? Inference within strata? Generalizability?
11/19/2009
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Analysis of Subgroups: Revisiting an old issue
E. Various Groups have legitimate interests
- Statisticians
* Pharmaceutical Industry
* FDA, other governmental agencies & Academia
- Clinicians
* Pharmaceutical Industry
* FDA, other governmental agencies & Academia (Med. Univ.s)
- Practicing Physicians
- Public Health Professionals
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Overview of Discussion
1. Randomized Controlled Trials
2. Why or why not perform subgroup analyses?
3. Test of treatment effect in subgroups
A. False Positives
- Simulation study (Brookes et al.) & Statistical Remedies

B. False Negatives
- Test of interaction & Sample size & power considerations (Brookes et al.)

4. Procedures for Subgroup Analyses
A. Matching criteria
- Notation, Propensity Score, Mahalanobis, Genetic, Example
B. Randomization & Population Model Inference
C. Randomization test and confidence intervals with Example
5. General guidelines to consider.
6. Summary
Appendix: Outline of Flexible Testing Strategy (Huque/ Alosh)
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1. Randomized Controlled Trials (RCTs)
•

Why conduct RCTs?
–
–

RDBCT is the gold standard for evidence
Analyses of large randomized controlled trials and systematic
reviews (e.g. correct meta-analyses of RCTs) are the most
reliable methods for determining the effects of treatments
(Rothwell, 2005).

•

Rational Criteria for World Health Care Planning
–

11/19/2009

"There is simply no serious scientific alternative to the
generation of large-scale randomized evidence. If trials can be
vastly simplified, …, and thereby made vastly larger, then they
have a central role to play in the development of rational
criteria for the planning of health care throughout the world."
--- Peto, et al (1995)
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1. Randomized Controlled Trials (RCTs)
•

Purpose of first RCTs.
– When trials were first developed for use in
agriculture, researchers were presumably concerned
about the effect of interventions on the overall size
and quality of the crop rather than on the well-being
of any individual plant.

•

Individualized medicine.
– In modern medical practice, clinicians frequently
need to make decisions about individuals, and how
best to use results of RCTs and systematic reviews
to maximize the well-being of each patient.

11/19/2009
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2. Why or why not Perform Subgroup analyses?
- Why Perform Subgroup Analysis?

•

Recruitment of a large number of eligible patients from
a general population is both a major strength and
weakness of large pragmatic trials.
–

•

Deliberately broad and sometimes generously-defined entry
criteria mean that the overall result can be difficult to apply to
particular groups.

Subgroup analyses are necessary if heterogeneity of
treatment effect is likely to occur.

11/19/2009
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2. Why or why not Perform Subgroup analyses?
- Arguments against Subgroup Analyses

•

Statisticians and non-clinical epidemiologists have
warned about the dangers of subgroup analyses and
other attempts to target treatment:
–

Application of False positive subgroup findings may be harmful
to patients; such findings may be more common than genuine
heterogeneity due to multiplicities or data dredging.

–

Qualitative heterogeneity of relative treatment effect (benefit in
one subgroup and harm in another) is rare. Statistical testing
rarely reveals any significant findings.

11/19/2009
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2. Why or why not Perform Subgroup analyses?
- Arguments for Subgroup Analyses

•

Clinician's warning of the dangers of applying the
overall results of large trials to individual patients
without consideration of pathophysiology or other
determinants of individual response.

•

“ . . . It would be unfortunate if the desire for the
perfect (i.e., knowledge of exactly who will benefit from
treatment) were to become the enemy of the possible
(i.e., knowledge of the direction and approximate size of the
effects of treatment for wide categories of patients).”
-- S. Yusuf et al. (1984)
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2. Why or why not Perform Subgroup analyses?
- Arguments for Subgroup Analyses

•

“The tragedy of excluding cogent pathophysiologic
subgroup analyses merely because they happen to
be subgroups will occur if statisticians do not know
the distinction, and if clinicians who do know it remain
mute, inarticulate or intimidated.” A Clinicostatistical
Tragedy.
-- A R Feinstein (1998)

•

“Far better an approximate answer to the right
question, which is often vague, than an exact answer
to the wrong question, which can always be made
precise.”
-- J W Tukey (1962)

11/19/2009
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2. Why or why not Perform Subgroup analyses?
- Arguments for Subgroup Analyses

“Many of the arguments used against subgroup analyses misinterpret
their main function. The main potential of subgroup analysis
is not in the identification of groups that differ in their
response to treatment for reasons of pathophysiology, but
is in answering practical questions about how treatments
should be used most effectively, such as at what stage of the
disease is treatment most effective, how soon after a clinical event is
treatment sufficiently safe or most effective, or how are the risks and
benefits related to comorbidity? Subgroup analyses related to

questions of the practical application of interventions can
be vital to effective clinical practice.” -- Rothwell (2005)

11/19/2009

11

2. Why or why not Perform Subgroup analyses?
- Important Clinical Indications for Subgroup Analyses
(Rothwell, 2005)

• Potential heterogeneity of treatment effect related to risk
– Differences in risks of treatment
– Differences in risk without treatment

• Clinically important questions related to the practical
application of treatment
–
–
–
–

Does benefit differ with severity of disease?
Does benefit differ with stage in the natural history of disease?
Is benefit related to the timing of treatment after a clinical event?
Is benefit dependent on comorbidity?

11/19/2009
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2. Why or why not Perform Subgroup analyses?
- Important Clinical Indications for Subgroup Analyses
(Continued: Rothwell, 2005)

• Potential heterogeneity of treatment effect related to
pathophysiology
– Multiple pathologies underlying a clinical syndrome.
– Differences in the biological response to a single pathology.
– Genetic variation.

• Underuse of treatment in routine clinical practice due to
uncertainty about benefit
– Underuse of treatment in specific groups of patients, e.g., in the
elderly.
– Confining treatment according to a narrow range of values of
relevant physiological variables, e.g., treatment thresholds for
cholesterol level or blood pressure.
11/19/2009
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3. Test of Treatment Effect in Subgroups
- Categories of Statistical Concerns

A. False positives – multiplicities of tests
B. False negatives – interaction tests
- Findings From a Large Simulation Study

(Brookes et al. (2004): J. Clin. Epidemiology)

11/19/2009
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3. Test of Treatment Effect in Subgroups
A. False Positive Concerns (Brookes et al.)

Table 5: Summary of FPRs of Tests of No Differential Subgroup Effect
True
overall
Rx effect

Rx effect
=0

Rx effect
0

11/19/2009

Observed
overall
Rx effect

Both subgroup tests
significant

One
subgroup
test
significant

Neither
subgroup
test
significant

Same
direction

Opposite
direction

Not
significant

0%

< 1%

7%

93%

Significant

2.5%

0%

64%

33%

Not
significant

0%

< 1%

21%

79%

Significant

33%

0%

57%

10%
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3. Test of Treatment Effect in Subgroups
A. False Positive Concerns:
Statistical Remedies for Multiplicities in Subgroup Analysis

• Multiple test adjustment:
– Bonferroni, Holm, or bootstrap method (Westfall & Young), etc.

• Use closed or hierarchical testing procedures.
• Spending proportions of α-level properly on subgroup
analyses within the total Type-I error rate.
- Huque & Alosh (2008): „α-spending‟ and heirarchical? Strongly
controls the FWER.

• Improve the precision of the endpoint measurement in
the subgroups.
• Choose and justify a different minimum standard of
efficacy for subgroups.
11/19/2009
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3. Test of Treatment Effect in Subgroups
B. False Negative Concerns: – Interaction Tests
Quantitative & Qualitative Interaction (Gail & Simon – 1985)

Remark: δi = treatment effect in the ith subgroup. Off diagonal
areas in quadrants 1 and 3 indicate quantitative interaction.
Quadrants 2 & 4 indicate qualitative interaction.
11/19/2009
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3. Test of Treatment Effect in Subgroups
B. Statistical Tests of Interaction

•

D. Cox (International Statistical Review, 1984)

•

A. Gonzalez & D. Cox (Annals of Applied Stat, 2007)

•

E. Russek-Cohen & R. Simon (Biometrics, 1993)

•

M. Silvapulle (Biometrics, 2001)

11/19/2009
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3. Test of treatment effect in subgroups.
B. Test of interaction.
Sample size & power considerations (Brookes et al.)
Frequency of Significant Interaction Tests As a Function of Relative Size

11/19/2009

19

3. Test of treatment effect in subgroups.
B. Test of Interaction
Sample Size Inflation Factor (Brookes et al), when
Power(Test for interaction) = Power(Test for treatment effect)

11/19/2009
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4. Procedures for Subgroup Analysis
A. Matching
•

Match subjects with similar background to reduce
imbalance:
–

Matching criteria:
•
•
•

–

•

Dividing the values of covariates.
Propensity score.
Mahalanobis distance, Genetic algorithm.

Matching covariates should be based on clinical relevance.

Divide subjects into a few “homogeneous” strata.
Estimate treatment effect within each stratum. Overall
result can be derived by aggregation.

11/19/2009
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4.A.1 Statistical Procedures - Notations
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4.A.2 Propensity Score Matching
(Rosenbaum & Rubin; 1983)

11/19/2009
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4.A.2.1 Remarks on Propensity Score Est.
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4.A.2.1 Remarks on Propensity Score Est.
•

According to Rosenbaum & Rubin (1983), it is
advantageous to sub-classify or match not only on
e(x) but for other functions of x as well;

•

In particular, such a refined procedure may be used
to obtain estimates of the average treatment effect in
subpopulations defined by components of x, for
example, males and females.

11/19/2009
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4.A.3 Mahalanobis & Genetic Matching
(Diamond & Sekhon; 2006)

11/19/2009
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4.A.4 Example for Illustration
•

A rheumatoid arthritis study:
–

•

Sample sizes and baseline comparisons:
–
–
–

•

A phase III, multicenter randomized, double blind, placebo
controlled comparative study of A or B in combination with
methotrexate in controlling disease activity in subjects with
rheumatoid arthritis having an inadequate clinical response
(DAS_28J) to methotrexate.
A group: 156; B group: 165; Placebo group: 110.
All baseline variables were balanced according to t-test.
No direct comparison between A and B in design.

Objective of this example: to compare A with B after 6
months of treatment.

11/19/2009
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4.A.4.1 Balancing Baseline CRP values via
Propensity Score Matching

11/19/2009
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4.A.4.2 Balancing Baseline CRP values via
Genetic Matching
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4.A.4.3 Balancing Baseline Pain Score via
Propensity Score Matching
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4.A.4.4 Balancing Baseline Pain Score via
Genetic Matching

11/19/2009
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4.B Randomization & Population Model Inference
• Randomization model:
– The basis for inference in the randomization model is the
random assignment of patients to treatments.
– It is not necessary to have random sample from a population
with specific distribution.
– Strictly speaking, normal theory methods are not appropriate
since their distribution theory depends on random sampling.
– Any inferences from randomization model are limited to the
subjects in the study (i.e. a local inference).

• Population model:
– The basis for inference in the population model is the random
sample from a population with specific distribution.
– Any inference from sample can be generalized to the whole
population.
11/19/2009
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4.B.1 Comparison of Pre & Post Matching Estimate of
Rx Effect – A Simulation: Response = DAS_28J;
Baseline Covariates = (age, pain, crp, #tend_J, #swol_J, haq)
(1) Combine data from group A and group B (call this sample S).
(2) From S, randomly sample 156 subjects and call this new Group A. The rest
is new Group B (to perform permutation test)
(3) Estimate treatment effect (mean difference) Using new Group A and new
Group B. No matching here.
(4) Using the same sample as in step 3 above, Genetically match subjects on
covariates in new Group A and new Group B. Then estimate treatment
effect.
(5) Form difference in estimated Treatment effects from step 3 (no matching)
and step 4 (genetic matching).
(6) Repeat steps 2 to 5 for 400 times, producing 400 differences between
estimates of treatment effect with matching and no matching. Note: There
are C321(156) = 321!/156!165! possible samples.
(7) Sort the 400 differences from step 6 and plot frequency distribution and
generate QQ plot.
11/19/2009
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4.B.1 Comparison of Pre & Post Matching Estimate of
Rx Effect – A Simulation: Response = DAS_28J;
Baseline Covariates = (age, pain, crp, #tend_J, #swol_J, haq)

11/19/2009
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4.B.2 Randomization Test of Pre & Post Matching
Rx Effect: (Pre Est = -0.19 & Post Matching = -0.048)
A Simulation

11/19/2009
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4.B.3 Randomization Upper Confidence Limit
(Robbins-Monro Stochastic Approx.)
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4.B.4 Randomization Lower Confidence Limit
(Robbins-Monro stochastic approx.)

11/19/2009

37

4.B.5 95% CI of Rx Effect Difference
(Based on Randomization Test: 5000 iterations)

Robbins-Monro Estimate of 95% CI = (- 0.110, 0.4858)
11/19/2009
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Example Summary
• Matching is a „type of covariate adjustment‟
• The adjustment derives from the matching on
clinically important covariates rather than from
entering covariates in some analysis model
• Inference on treatment effect (-0.048) is from the
permutation distribution of the matched data
(Pre Est = -0.19); and
• CIs from Robbins-Monro: 95% CI = (-0.110; 0.4858)
- which requires one-sided permutation tests in
search of LL and UL.
11/19/2009
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5. General Guidelines for Subgroup Analysis (1)
• Pre hoc:
– Pre-specify the subgroup analyses, the magnitude and direction of the
hypothesized subgroup effects; i.e. correctly specify the question
– Consider subgroups based on clinically important covariates.
– The number of subgroup analysis should be kept small and well
documented
– If feasible, adequately power planned subgroup analyses.
– Test for treatment and subgroup interaction to investigate whether the
effect is different among subgroups.

• Post hoc:
– Properly match subjects to reduce the potential bias due to the lack of
randomization.
– Post hoc findings should be regarded as exploratory and useful for
hypothesis generating.

11/19/2009
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5. General Guidelines for Subgroup Analysis (2)
• Interpretation:
– The lack of statistical significance only implies the inadequate
conviction of effect from the data base.
– Statistical significant findings of effect should not be
overemphasized.
– Post hoc findings are not automatically invalid, many medical
discoveries have been fortuitous; e.g. Penicillin.
– Interpret the findings in the context of biological plausibility and
clinical relevance.

• Final verdict:
– The best measure of the validity of subgroup effects is
independent verification in another trial.
11/19/2009
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6. Summary
• Interpretation of findings:
– The lack of statistical significance only implies inadequate
conviction of effect from the data analyzed;
– „Statistically significant findings‟ of effect should not be
overemphasized;
– Post hoc findings are not automatically invalid, many medical
discoveries have been fortuitous. e. g. Penicillin
– Interpret findings within the context of biological plausibility and
clinical relevance with proper intelligence.

• A better verdict:
– A better measure of the validity of subgroup effects is through
independent verification in the proper context if feasible.
11/19/2009
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6. Summary (cont’d)
• The crux of scientific exploration:
– Positive findings should not be dismissed automatically just
because they are counter-intuitive or can‟t be interpreted
plausibly.
– Negative findings should not conclude automatically as no effect.
According to Dr. Robert Temple of the FDA, about 46% of wellconducted trials of effective antidepressants cannot distinguish
drug from placebo [see Leber (1983) Control CTs Soc. Mtg].
– Sir Isaac Newton once said, “Great discoveries are often
achieved off the beaten paths.” Minoxidil, AZT?

11/19/2009
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6. Summary (cont’d)
Do subgroup analysis results have a place in the realm of scientific inference
(Peace; 1994)?
- Maybe so, maybe not
Suppose proper subgroup analyses lead to statistically significant treatment effects in
two subgroups (Post Hoc). Can we infer that treatment effect has been confirmed?
And therefore meet the two adequate and well controlled requirement?

If such results are viewed as reproducible, their level of scientific credibility would not
be as great as that from results of two prospective CTs (or two identified subgroups
within a CT) where there was a commitment to the questions and methods

- Have a place in labeling efforts
One has established that new drug is effective. Explore entire database using
interaction tests of treatment and subpopulations (FDA Demographic Rule).
Lack of significant interaction lends support to overall effect being consistent across
subpopulations
For significant interactions perform subgroup analyses to obtain CIs on treatment
effect in subpopulations. Qualitative interactions could be very important.
11/19/2009
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Appendix: Outline of Flexible Testing Strategy
(Huque and Alosh; 2008):

H0: δ = 0 (or δ ≤ 0, 1-sided hypothesis) is the null hypothesis
for the overall population,
H0s : δs = 0 (or δs ≤ 0, 1-sided hypothesis) is the null
hypothesis for the targeted subgroup,
T = test statistic is used for testing H0,

Ts = test statistic is used for testing Hs, and
(p, ps) = observed p-values for the testing of H0 and H0s ,
respectively.

11/19/2009
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Appendix: Outline of Flexible Testing Strategy
(Huque and Alosh; 2008):
Testing strategy is summarized in the following steps:

Step 1: Reject H0 at level α0 if T > C1;1− α0 ; where α0 < α .
Step 2:
(a) If H0 is rejected in Step 1, then test H0s at the full significance
level of α; i.e. reject H0s if Ts > C2;1− α.
(b) If H0 is not rejected in Step 1, and α0 < p < α* (α* is prespecified, e.g. 0.10 for 1-sided p); then test H0s at the reduced
significance level of αs, where α − α0 < αs ≤ α, i.e. reject H0s if
Ts > C2;1−s. If α* is in the interval (α0; α], then set αs = α.
(c) If p> α*, do not test for H0s .
This testing strategy strongly controls the family wise error rate
(FWER). Huque and Alosh provide tables for αs for specified
values of α0 , α and ρ.
11/19/2009
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Appendix: Flexible Testing Strategy
(Huque and Alosh; 2008):
When designing a clinical trial in which the interest is in establishing
efficacy in one or more subgroups, in addition to that of the overall study
population, several factors need to be considered at the design stage:
- pre-specification of hypotheses to be tested for subgroups and the
overall population, and
- powering the study overall along with powering for subgroups.
The flexible testing strategy controls Type I error rate and permits testing
for the subgroup after taking into account the need for a certain degree of
efficacy consistency between the overall study population and that of
subgroup. Computation shows that the power of the subgroup is an
increasing function of the estimate of the correlation as well as treatment
effect in the subgroup relative to that of the total study population. As a
consequence of these observations, it is critical at the design stage to use
conservative estimate for the correlation and subgroup treatment effect to
reduce the chance of under powering the study for the subgroup.
11/19/2009
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Notes:
• CRP = C-Reactive Protein; a marker of inflammation
• Example: A & B were biologics. One was a Cytokine Inhibitor of TNF
(tumor necrosis factor - may regulate immune cells & have a role in
inflammation)
• Baseline covariates: AGE, PAIN, CRP, #TEND, #SWOL, HAQ
• Inflation factor (Brookes): is a multiple
• Interpretation of QQ plots: Identical if on y = x; flatter or steeper
means more dispersed; arced or S means skewness or one is more
heavy tailed.
• Strong Ignorability: P[T| X] = P[T].
• In MHD and Genetic matching, i and j index treatment group. For
every subject in A and every subject in B, their proximity in terms of
their covariates is calculated according to the formula of GMD. In the
end, there will be a big 156-by-165 matrix of proximities. Aggregate
the subjects in A and subjects in B with good proximity and estimate
the Rx difference. This is similar to Cluster Analysis.
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Notes re R-Matching
http://sekhon.berkeley.edu/library/Matching/
•

•

•

•

•

multivariate matching using the Mebane & Sekhon (1998) genetic search
algorithm to determine the weight each covariate is given. Balance is
determined by examining cumulative pdfs of a variety of standardized
statistics. By default, these statistics include t-tests and KolmogorovSmirnov tests. Many descriptive statistics based on empirical-QQ plots can
be used or any user provided measure of balance.
The statistics are not used to conduct formal hypothesis tests, because no
measure of balance is a monotonic function of bias and because balance
should be maximized without limit.
The object returned by GenMatch can be supplied to the Match function (via
the Weight.matrix option) to obtain causal estimates.
GenMatch uses genoud to perform the genetic search. Using the cluster
option, one may use multiple computers, CPUs or cores to perform parallel
computations
Robbins-Monro: Theta-hat is the treatment difference from the 2 samples.
Every time a new sample is simulated, theta-hat is updated. Therefore, it
affects Ui too. This is not a part of R-GenMatch; was programmed in R.
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Results of Six Trials of Exp. Antidepressant (NEW), Imipramine (IMI) and PBO
(PBO Data Concealed); HAM_D_S) Mean Scoresa at last visitb Leber: 1983

Common
baseline

Drug

Sample
Size

HDS

p Value

Study 1

2.39

NEW
IMI

33
33

13.4
12.8

0.78

Study 2

26.0

NEW
IMI

39
30

13.0
13.4

0.86

Study 3

28.1

NEW
IMI

11
11

19.4
20.3

0.81

Study 4

29.6

NEW
IMI

7
8

7.3
9.5

0.63

Study 5

37.6

NEW
IMI

7
8

21.9
21.9

1.00

Study 6

26.1

NEW
IMI

37
32

11.2
10.8

0.85

aScores

adjusted by analysis of covariance
bScore at 4 weeks or, if none available, last score available prior to 4 weeks
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Results of Six Trials of Exp. Antidepressant (NEW), Imipramine (IMI)
and PBO; HAM_D_S) Mean Scoresa at last visitb Leber: 1983
Common baseline

Drug

Sample Size

HDS

Study 1

2.39

NEW
IMI
PBO

33
33
36

13.4
12.8
14.8

Study 2

26.0

NEW
IMI
PBO

39
30
36

13.0
13.4
13.9

Study 3

28.1

NEW
IMI
PBO

11
11
13

19.4
20.3
18.9

Study 4

29.6

NEW
IMI
PBO

7
8
7

7.3
9.5
23.5c

Study 5

37.6

NEW
IMI
PBO

7
8
8

21.9
21.9
22.0

Study 6

26.1

NEW
IMI
PBO

37
32
36

11.2
10.8
10.5

aScores

adjusted by analysis of covariance
at 4 weeks or, if none available, last score available prior to 4 weeks
cNEW, IMI better than PBO, p<0.001
bScore
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